



Role of Endomucin in Hypoxia-Induced Retinopathy of Prematurity

## Journal of Health Disparities Research and Practice

Volume 9  
Issue 5 *Special Issue - NIDDK STEP UP*

Article 78

© Center for Health Disparities Research, School of Public Health, University of Nevada, Las Vegas

2016

### Role of Endomucin in Hypoxia-Induced Retinopathy of Prematurity

James Salvador Niffenegger

Cindy Park-Windhol, PhD , *Harvard Medical School*

Patricia A. D'Amore, PhD, MBA , *Harvard Medical School*

Follow this and additional works at: <https://digitalscholarship.unlv.edu/jhdrp>



Part of the [Bilingual, Multilingual, and Multicultural Education Commons](#), [Community College Leadership](#)

[Commons](#), [Higher Education Commons](#), [Immune System Diseases Commons](#), [Public Health Commons](#), [Translational Medical Research Commons](#), and the [Virus Diseases Commons](#)

#### Recommended Citation

Salvador Niffenegger, James; Park-Windhol, PhD, Cindy; and D'Amore, PhD, MBA, Patricia A. (2016) "Role of Endomucin in Hypoxia-Induced Retinopathy of Prematurity," *Journal of Health Disparities Research and Practice*: Vol. 9: Iss. 5, Article 78.

Available at: <https://digitalscholarship.unlv.edu/jhdrp/vol9/iss5/78>

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in Journal of Health Disparities Research and Practice by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact [digitalscholarship@unlv.edu](mailto:digitalscholarship@unlv.edu).

---

## Role of Endomucin in Hypoxia-Induced Retinopathy of Prematurity

### Abstract

Retinopathy of prematurity (ROP) is a major cause of blindness among premature, low birth weight infants as a result of pathological angiogenesis. Angiogenesis, the growth of new blood vessels from preexisting vessels, occurs in the veins and capillaries of the body. The process is highly regulated during early development and maturation. However, under abnormal conditions such as a decrease in oxygen levels or hypoxia, angiogenesis can become dysregulated and pathogenic. Currently, the best treatment for ROP is laser therapy, which does not significantly improve vision. Alternatively, glycoproteins are believed to play an important role in angiogenesis. Endomucin (EMCN), a glycoprotein, has been shown to be expressed by the venous and capillary endothelium. EMCN is believed to be associated with angiogenesis and could be a potential target for treatment of ROP. Thus, we hypothesize that EMCN is regulated by hypoxia and plays an important role in pathological angiogenesis.

Human retinal endothelial cells (HRECs), representative of endothelial cells involved in retinal angiogenesis, were deprived of oxygen using a hypoxia chamber. We established the optimal oxygen dosage, determined the optimal cell density, and monitored EMCN expression at different time points after exposure to hypoxia. Changes in gene expression in response to hypoxia were compared to control cells. Our preliminary data indicates that EMCN is regulated by hypoxia. Currently, we are investigating whether EMCN has similar effects in regulating revascularization in vivo. Taken together, our study indicates a novel role for EMCN during hypoxia-induced angiogenesis which may serve as a therapeutic target.

### Keywords

angiogenesis; endomucin; hypoxia



**Journal of Health Disparities Research and Practice**  
**Volume 9, Special Edition 1, Summer 2016, pp. 113**  
© 2011 Center for Health Disparities Research  
School of Community Health Sciences  
University of Nevada, Las Vegas

## **Role of Endomucin in Hypoxia-Induced Retinopathy of Prematurity**

James Salvador Niffenegger

Cindy Park-Windhol, PhD, Harvard Medical School

Patricia A. D'Amore, PhD, MBA, Harvard Medical School

**Coordinating Center:** Stanford University

### **ABSTRACT**

Retinopathy of prematurity (ROP) is a major cause of blindness among premature, low birth weight infants as a result of pathological angiogenesis. Angiogenesis, the growth of new blood vessels from preexisting vessels, occurs in the veins and capillaries of the body. The process is highly regulated during early development and maturation. However, under abnormal conditions such as a decrease in oxygen levels or hypoxia, angiogenesis can become dysregulated and pathogenic. Currently, the best treatment for ROP is laser therapy, which does not significantly improve vision. Alternatively, glycoproteins are believed to play an important role in angiogenesis. Endomucin (EMCN), a glycoprotein, has been shown to be expressed by the venous and capillary endothelium. EMCN is believed to be associated with angiogenesis and could be a potential target for treatment of ROP. Thus, we hypothesize that EMCN is regulated by hypoxia and plays an important role in pathological angiogenesis.

Human retinal endothelial cells (HRECs), representative of endothelial cells involved in retinal angiogenesis, were deprived of oxygen using a hypoxia chamber. We established the optimal oxygen dosage, determined the optimal cell density, and monitored EMCN expression at different time points after exposure to hypoxia. Changes in gene expression in response to hypoxia were compared to control cells. Our preliminary data indicates that EMCN is regulated by hypoxia. Currently, we are investigating whether EMCN has similar effects in regulating revascularization in vivo. Taken together, our study indicates a novel role for EMCN during hypoxia-induced angiogenesis which may serve as a therapeutic target.

**Keywords:** angiogenesis, endomucin, hypoxia

### **ACKNOWLEDGEMENTS**

The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, Grant number: R25DK078382.